A Phase I, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Potential Activity of HE3286 When Administered Orally to Obese Adult Subjects for 28 Days.

Trial Profile

A Phase I, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Potential Activity of HE3286 When Administered Orally to Obese Adult Subjects for 28 Days.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Jun 2015

At a glance

  • Drugs HE 3286 (Primary)
  • Indications Insulin resistance; Obesity; Type 2 diabetes mellitus
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Sponsors Harbor Therapeutics
  • Most Recent Events

    • 12 Nov 2009 Status changed from recruiting to completed according to a Hollis-Eden Pharmaceuticals media release. The final analysis of this trial is currently in progress.
    • 19 Jun 2009 Planned end date changed from 1 Sep 2008 to 1 Sep 2009 as reported by ClinicalTrials.gov.
    • 17 Nov 2008 Planned number of patients changed from 54 to 66, as reported by ClinicalTrials.gov. Trial centres updated.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top